Why Different Answer Engines Tell Different Stories About Your Drug
Michael Etheredge is VP of Product Development at QuestionFuel, where he leads how the firm measures and corrects the way AI answer engines describe companies. He was featured by the Southern Economic Development Council on how AI is changing the way companies research communities and regions.
Ask ChatGPT about your lead candidate. Then ask Claude. Then Gemini, then Perplexity. You will often get four different answers.
Not four phrasings of the same answer. Four genuinely different stories, sometimes emphasizing different trial results, different risks, different competitive positioning, and occasionally different facts altogether.
For a [life sciences](/life-sciences) company, this is more than a curiosity. The investors, analysts, physicians, and partners forming opinions about your drug aren't all using the same answer engine. They're spread across all of them. Which means there isn't one AI narrative about your company to manage. There are several, running in parallel, and they don't agree with each other.
Key takeaways
- Different answer engines give different answers about the same drug because each is trained on a different data mix and updated on a different schedule.
- Life sciences is hit hardest because drug narratives change in discrete, high stakes jumps such as readouts, label changes, and safety signals.
- Checking a single platform hides the problem, because one clean answer says nothing about the other three.
- Divergence widens right after major milestones, which is exactly when monitoring matters most.
- You cannot eliminate divergence, but you can measure it across platforms and narrow it by aligning the public record all of them read.
Quick answer: ChatGPT, Claude, Gemini, and Perplexity often describe the same drug differently because each model is trained on a different mix of sources, refreshed on a different schedule, and tuned to weigh clinical evidence differently. The result is several parallel narratives about your company rather than one. The gaps widen around readouts, approvals, and safety updates, so the only reliable way to see the real picture is to ask the same stakeholder questions across every major platform and compare the answers side by side.
Why does the same question get four different answers?
Large language models don't share a single source of truth. Each one is trained on a different mix of data, updated on a different schedule, and tuned with different methods for how it weighs and synthesizes what it finds. Some pull in live web results for certain queries. Others answer primarily from training data with a cutoff months in the past.
So when each model is asked the same question about your drug, it's effectively consulting a different library, frozen at a different moment, read through a different lens. The result is divergence: one platform leads with your positive primary endpoint, another foregrounds an adverse event from an earlier trial, a third describes a mechanism of action that's a generation out of date, and a fourth hedges everything because it isn't confident what's current.
None of them is necessarily malfunctioning. They're each doing exactly what they were built to do, with different inputs. The divergence is structural, not a bug.
Why does answer engine divergence hit life sciences harder than most industries?
Three features of the life sciences information environment make divergence across answer engines especially pronounced.
Drug narratives evolve in discrete, high stakes jumps. A readout, a label change, an approval, a safety signal. Each event sharply changes the correct answer. Because answer engines update on different schedules, at any given moment some will reflect the latest event and others won't, so they fall out of sync precisely around the moments that matter most.
The source material is dense, technical, and easy to misweight. Clinical data has primary endpoints, secondary endpoints, subgroups, and adverse events, all carrying different significance. Different models weigh these differently, and a secondary or negative finding can get foregrounded by one platform while another leads with the headline result.
The history is long and never disappears. Earlier phase results, discontinued indications, and superseded mechanisms persist in training data long after they've been overtaken. One model may surface a three-year-old framing as if it were current, while another has moved on.
Put together, these mean a life sciences company can have a meaningfully different AI narrative on each major platform, with the gaps widening exactly when a drug hits a clinical or regulatory milestone. This is one of the more concrete forms of narrative drift that life sciences teams encounter.
Why does checking a single answer engine miss the problem?
The most common way companies first look at this problem is also the way that hides it: they ask one answer engine one question, see a reasonable answer, and conclude the AI narrative is fine.
But one platform is one library. A clean answer from ChatGPT tells you nothing about what Gemini is telling a physician or what Perplexity is telling an analyst. The divergence is invisible to anyone checking a single source, which is why companies are often surprised to learn how differently they're described once they look across platforms side by side.
Seeing the real picture requires checking the same set of questions across the major platforms and comparing the answers against each other, not just against reality. The gaps between the platforms are as important as the gaps between any one platform and the truth.
What can a company do about answer engine divergence?
Divergence across answer engines can't be eliminated. You don't control how these models are trained or updated, and you never will. But it can be measured and narrowed, which is exactly what the DRIFT Framework is built to do.
Measure across platforms, not on one. Establish a baseline of how ChatGPT, Claude, Gemini, and Perplexity each describe your company, your pipeline, and your key candidates, using the same questions a real investor, analyst, or physician would ask. The comparison is the point.
Find where they diverge and why. Some divergence comes from one platform lagging on a recent event. Some comes from different models weighting your data differently. The cause determines the fix.
Align the underlying sources. Answer engines synthesize from the public record. When that record is clear, current, and consistent, the platforms have less room to drift apart. You can't update the models, but you can improve what they read.
Re-check around milestones. Because divergence widens around readouts, approvals, and safety updates, that's when monitoring matters most. The period right after a major event is when the platforms are most likely to disagree.
The bottom line: how many AI narratives does your company have?
There is no single AI narrative about your drug. There are several, one per platform, each built from a different library frozen at a different moment, and they routinely disagree, most of all around the milestones that matter.
Managing that means looking across all of them at once, understanding why they diverge, and steadily aligning the public record they draw from. A company that checks only one platform isn't seeing its AI narrative. It's seeing a quarter of it.